68 related articles for article (PubMed ID: 31155491)
1. Advancing Second-Line Treatment for Primary Biliary Cholangitis.
Assis DN
N Engl J Med; 2024 Feb; 390(9):853-854. PubMed ID: 38381658
[No Abstract] [Full Text] [Related]
2. Editorial: The evolving paradigms and treatments for primary biliary cholangitis.
Vuppalanchi R; Kowdley KV
Aliment Pharmacol Ther; 2024 Jan; 59(2):280-281. PubMed ID: 38153286
[No Abstract] [Full Text] [Related]
3. Optimizing treatment of primary biliary cholangitis: Is good, good enough?
Bowlus CL; Levy C
Hepatology; 2024 Jan; 79(1):3-5. PubMed ID: 37526603
[No Abstract] [Full Text] [Related]
4. Primary Biliary Cholangitis: Epidemiology, Diagnosis, and Presentation.
Faisal MS; Gonzalez HC; Gordon SC
Clin Liver Dis; 2024 Feb; 28(1):63-77. PubMed ID: 37945163
[TBL] [Abstract][Full Text] [Related]
5. Letter: histology is relevant for risk stratification in primary biliary cholangitis.
Carbone M; D'Amato D; Hirschfield GM; Jones DEJ; Mells GF
Aliment Pharmacol Ther; 2020 Jan; 51(1):192-193. PubMed ID: 31850571
[No Abstract] [Full Text] [Related]
6. Editorial: Unravelling real-world impact of second-line therapies in primary biliary cholangitis- Time to change our targets?
Cançado GGL
Aliment Pharmacol Ther; 2024 Jul; 60(1):89-90. PubMed ID: 38773759
[No Abstract] [Full Text] [Related]
7. Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis.
Talwalkar JA
Liver Int; 2008 Jul; 28(6):761-3. PubMed ID: 18647139
[No Abstract] [Full Text] [Related]
8. Elafibranor in primary biliary cholangitis.
Kotsiliti E
Nat Rev Gastroenterol Hepatol; 2024 Jan; 21(1):2. PubMed ID: 38036746
[No Abstract] [Full Text] [Related]
9. Primary biliary cholangitis with features of autoimmune hepatitis in a 19-year-old adolescent with 14q24.1q24.2 deletion: a case report.
Wang YW; Chao HC; Wang HS; Lin JL; Chang CC; Huang SF
Front Pediatr; 2023; 11():1280409. PubMed ID: 38152650
[TBL] [Abstract][Full Text] [Related]
10. Overview of autoimmune liver disease: Prevalence, risk factors, and role of autoantibodies.
Xi D; Lin H; Shah AA
Clin Liver Dis (Hoboken); 2022 Oct; 20(4):111-115. PubMed ID: 36245681
[TBL] [Abstract][Full Text] [Related]
11. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
Stiefelhagen P
MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
[No Abstract] [Full Text] [Related]
12. [Primary biliary cirrhosis and ursodeoxycholic acid therapy].
Makino I
Nihon Naika Gakkai Zasshi; 1996 Mar; 85(3):399-403. PubMed ID: 8691003
[No Abstract] [Full Text] [Related]
13. [New name and new treatments for primary biliary cholangitits].
Bossen L; Ytting H; Jepsen P; Hamberg O; Ott P; Grønbæk H
Ugeskr Laeger; 2018 Mar; 180(10):. PubMed ID: 29536837
[TBL] [Abstract][Full Text] [Related]
14. Pediatric-onset primary biliary cholangitis.
Liberal R; Gaspar R; Macedo G
Dig Liver Dis; 2019 Jul; 51(7):1064-1065. PubMed ID: 31155491
[No Abstract] [Full Text] [Related]
15. Primary biliary cholangitis, let's try to keep the new nomenclature correct!
Harinck F
Neth J Med; 2016 Jul; 74(6):229-30. PubMed ID: 27571719
[No Abstract] [Full Text] [Related]
16. Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
Schattenberg JM
Gut; 2020 Aug; 69(8):1377-1378. PubMed ID: 32205421
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
